Source-grounded facts extracted from Zentalis Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Zentalis Pharmaceuticals, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-16 meeting.
“Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,949,844 10,930,673 47,136 16,526,113”
Zentalis Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-16 meeting.
“Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 49,321,951 13,557 118,258 0”
Zentalis Pharmaceuticals, Inc. shareholders approved Election of two Class III directors to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-16 meeting.
“Item 1 — Election of two Class III directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes David Johnson 20,711,869 12,215,784 16,526,113 Jan Skvarka, Ph.D. 23,497,184 9,430,469 16,526,113”
Shannon Campbell was appointed as Director at Zentalis Pharmaceuticals, Inc..
“Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.”
Zentalis Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 12, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026”
Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.”
Zentalis Pharmaceuticals, Inc. announced a restructuring with charges of approximately $7.0–8.0 million affecting the Company (approximately 40%).
“On January 22, 2025, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) approved a strategic restructuring of the Company to support execution of late-stage development for the Company’s WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a potentially registration-enabling azenosertib data readout from the Company’s DENALI Part 2 study, anticipated by the end of 2026. In connection with this strategic restructuring, the Company expects to reduce its workforce by approximately 40%. The Company expects to incur one-time costs of approximately $7.0–8.0 million in the first quarter of 2025 in connection with the workforce reduction.”
Kimberly Blackwell resigned as Chief Executive Officer and Director at Zentalis Pharmaceuticals, Inc..
“Also on November 12, 2024, Kimberly Blackwell, M.D., resigned as Chief Executive Officer, a member of the Board and from all other positions held with the Company and its affiliates, effective on the Transition Date.”
Julie Eastland was appointed as Chief Executive Officer, President and a Class I director at Zentalis Pharmaceuticals, Inc..
“On November 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company’s 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the “Transition Date”).”
Luke Walker, M.D. was appointed as Director at Zentalis Pharmaceuticals, Inc..
“On and effective May 24, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Luke Walker, M.D., as a Class II director.”
Zentalis Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 7, 2024, Zentalis Pharmaceuticals, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024 and commented on certain business updates.”
Vincent Vultaggio was appointed as interim principal accounting officer at Zentalis Pharmaceuticals, Inc..
“the Company’s Vice President, Finance, Vincent Vultaggio, as interim principal accounting officer”
Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2023.
“On February 27, 2024, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023”
Zentalis Pharmaceuticals, Inc.: Amended and Restated Bylaws to address universal proxy rules, streamline stockholder nomination procedures, and prohibit excessive director nominees; effective February 12, 2024 (effective 2024-02-12).
“On February 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) approved and adopted amendments to the Company’s Bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.”
Diana Hausman resigned as Director at Zentalis Pharmaceuticals, Inc..
“Dr. Hausman resigned from the Board, the Audit Committee of the Board (“Audit Committee”), and the Nominating and Corporate Governance Committee of the Board.”
Carrie Brownstein departed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc..
“Dr. Brownstein stepped down for personal reasons.”
Diana Hausman was appointed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc..
“On January 25, 2024, Zentalis Pharmaceuticals, Inc. (the “Company” or “Zentalis”) announced that Diana Hausman, M.D., a member of the Company’s Board of Directors (the “Board”), had succeeded Carrie Brownstein, M.D. as Chief Medical Officer of the Company, effective January 19, 2024”
Zentalis Pharmaceuticals, Inc. reported financial results for quarter ended September 30, 2023.
“On November 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023 and commented on certain business updates.”
Iris Roth departed as Chief Operating Officer at Zentalis Pharmaceuticals, Inc..
“On Friday, October 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced that Iris Roth, Ph.D., Chief Operating Officer of the Company, will depart from the Company and cease serving as Chief Operating Officer of the Company, effective as of 11:59 p.m. Eastern Time on Tuesday, October 10, 2023.”
Zentalis Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.
“Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023”
Zentalis Pharmaceuticals, Inc.: Amended certificate of incorporation to update exculpation provision for certain officers as permitted by Delaware law (effective 2023-06-16).
“On June 16, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (the “Amendment”), which had previously been adopted by the Company’s Board of Directors (the “Board”) subject to stockholder approval at the Annual Meeting.”
Zentalis Pharmaceuticals, Inc. shareholders rejected Advisory (non-binding) approval of the compensation of the Company's named executive officers.
“Item 4 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.”
Zentalis Pharmaceuticals, Inc. shareholders approved Approval of an amendment to the Company's Certificate of Incorporation to update the exculpation provision with respect to certain officers of the Company as permitted by the General Corporation Law of the State of Delaware.
“Item 3 — Approval of an amendment to the Company's Certificate of Incorporation to update the exculpation provision with respect to certain officers of the Company as permitted by recent amendments to the General Corporation Law of the State of Delaware.”
Zentalis Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting.
“Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Zentalis Pharmaceuticals, Inc. shareholders approved Election of two Class III directors to serve until the 2026 Annual Meeting of Stockholders.
“Item 1 — Election of two Class III directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal.”
Zentalis Pharmaceuticals, Inc. reported financial results for quarter ended March 31, 2023.
“On May 10, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023 and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K”
Zentalis Pharmaceuticals, Inc. entered into Sublease Agreement with LM Cohen & Co. LLP valued at Base rent approximately $1.5 million per annum for first five years, then $1.7 million per annum (effective 2023-03-06).
“On March 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) and LM Cohen & Co. LLP (the "Subtenant") entered into a Sublease Agreement (the "Sublease") pursuant to which the Subtenant will sublease the Company's office space located at 1359 Broadway, Suites 1710 and 1800, New York, NY 10018 (the "Premises"), which the Company leased under that certain Lease Agreement entered into on March 24, 2021 (the "Lease") between the Company and ESRT 1359 BROADWAY, L.L.C. (the "Landlord").”
Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.
“Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.”
Iris Roth was appointed as Chief Operating Officer at Zentalis Pharmaceuticals, Inc..
“On February 13, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) publicly announced the appointment of Iris Roth, Ph.D. as Chief Operating Officer of the Company, effective as of February 13, 2023”
Zentalis Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.
“Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates”
Kevin Bunker changed role as Chief Scientific Officer at Zentalis Pharmaceuticals, Inc..
“On and effective September 26, 2022, Kevin Bunker was promoted to Chief Scientific Officer of Zentalis Pharmaceuticals, Inc. (the “Company”) and, as a result of his promotion, stepped down as Chief Operating Officer of the Company.”
Jan Skvarka was appointed as Class III director at Zentalis Pharmaceuticals, Inc..
“On and effective September 9, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Jan Skvarka, Ph.D., M.B.A., as a Class III director.”
Alexis M. Pinto resigned as Chief Legal Officer and Secretary at Zentalis Pharmaceuticals, Inc..
“On June 21, 2022, Alexis M. Pinto notified Zentalis Pharmaceuticals, Inc. (the “Company”) of her resignation as Chief Legal Officer and Secretary of the Company, effective as of July 5, 2022.”
Kimberly Blackwell departed as President at Zentalis Pharmaceuticals, Inc..
“succeeding Kimberly Blackwell in such role”
Cam S. Gallagher was appointed as President at Zentalis Pharmaceuticals, Inc..
“On May 25, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the “Commencement Date”).”
Kimberly Blackwell was appointed as President and Chief Executive Officer at Zentalis Pharmaceuticals, Inc..
“the Board appointed Kimberly Blackwell, M.D., a current member of the Board, as President and Chief Executive Officer of the Company, and designated Dr. Blackwell as the Company’s principal executive officer, in each case effective as of the commencement of Dr. Blackwell’s employment with the Company, which is expected to be on or about May 16, 2022”
David M. Johnson was appointed as Chairman of the Board at Zentalis Pharmaceuticals, Inc..
“appointed David M. Johnson as Chairman of the Board, in each case effective as of the Resignation Effective Time”
Kevin M. Bunker was appointed as Principal Executive Officer (Interim) at Zentalis Pharmaceuticals, Inc..
“the Board designated Kevin M. Bunker, Ph.D., the Company’s Chief Operating Officer, as the Company’s principal executive officer on an interim basis”
Anthony Y. Sun resigned as Chairman of the Board at Zentalis Pharmaceuticals, Inc..
“On May 10, 2022, Anthony Y. Sun, M.D., notified Zentalis Pharmaceuticals, Inc. (the “Company”) of his resignation as President and Chief Executive Officer of the Company and as a director and Chairman of the Board of Directors of the Company (the “Board”), effective as of 11:59 p.m. on May 10, 2022”
Anthony Y. Sun resigned as President and Chief Executive Officer at Zentalis Pharmaceuticals, Inc..
“On May 10, 2022, Anthony Y. Sun, M.D., notified Zentalis Pharmaceuticals, Inc. (the “Company”) of his resignation as President and Chief Executive Officer of the Company and as a director and Chairman of the Board of Directors of the Company (the “Board”), effective as of 11:59 p.m. on May 10, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.